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HIV-1 assembly and release occur at the plasma
membrane in T lymphocytes, while intracellular sites
of virus assembly or accumulation are apparent in
macrophages. The host protein tetherin (BST-2)
inhibits HIV release from the plasma membrane by
retaining viral particles at the cell surface, but the
role of tetherin at intracellular HIV assembly sites is
unclear. We determined that tetherin is significantly
upregulated upon macrophage infection and local-
izes to an intracellular virus-containing compartment
(VCC). Tetherin localized at the virus-VCCmembrane
interface, suggesting that tetherin physically tethers
virions in VCCs. Tetherin knockdown diminished
and redistributed VCCs within macrophages and
promoted HIV release and cell-cell transmission.
The HIV Vpu protein, which downregulates tetherin
from the plasma membrane, did not fully overcome
tetherin-mediated restriction of particle release in
macrophages. Thus, tetherin is essential for VCC
formation and may account for morphologic differ-
ences in the apparent HIV assembly sites in macro-
phages versus T cells.
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) assembly
occurs predominantly at the plasma membrane of infected T
lymphocytes and model epithelial cell lines (Chu et al., 2009;
Finzi et al., 2007; Gelderblom, 1991; Jouvenet et al., 2006;
Ono and Freed, 2004). In contrast, infected macrophages
examined by electron microscopy and immunofluoresent
microscopic techniques demonstrate an intense intracellular
accumulation of virions in a compartment marked by charac-
teristic components of the multivesicular body (MVB),
including CD81, CD9, MHC class II, and CD63 (Nydegger
et al., 2003; Pelchen-Matthews et al., 2003; Raposo et al.,
2002; Sherer et al., 2003). The presence of apparent assembly
in intracellular sites with characteristics of the MVB in macro-
phages led to models for HIV-1 assembly in which the endo-
cytic network plays an important role. Some models for HIV-1360 Cell Host & Microbe 12, 360–372, September 13, 2012 ª2012 Elassembly in macrophages propose that intracellular assembly
predominates, with release from the intracellular compart-
ment across the virologic synapse upon contact with T cells
(Gousset et al., 2008; Groot et al., 2008; Montaner et al.,
2006). Defining the precise site of assembly in the macro-
phage and the factors determining the apparent intracellular
assembly site thus has relevance to a number of areas of
HIV biology.
Jouvenet and coworkers previously suggested that the
plasma membrane was the only site of HIV assembly in infected
macrophages, and that HIV particles observed in the intra-
cellular compartments resulted from endocytosis of viral parti-
cles from the cell surface (Jouvenet et al., 2006). Tetherin was
subsequently identified as an important HIV restriction factor
resulting in the retention of particles at the plasma membrane
of cells and leading to enhanced endocytosis of particles in
model cell lines (Neil et al., 2008). Tetherin, also known as
BST-2 or CD317, is an unusual type II membrane protein that
localizes to lipid rafts and is endocytosed through a clathrin-
and AP2-dependent mechanism (Masuyama et al., 2009; Rolla-
son et al., 2007). Tetherin is highly concentrated at the particle
budding site in T cell lines and plays a physical tethering role
in retaining strings of virions in cells infected with Vpu-deficient
virus (Hammonds and Spearman, 2009; Hammonds et al., 2010;
Perez-Caballero et al., 2009). Vpu overcomes the restrictive
effects of tetherin, resulting in enhanced particle release. The
mechanism of Vpu’s action in counteracting tetherin remains
to be fully elucidated, but retention of tetherin at intracellular
sites, downregulation of tetherin from the cell surface, and
enhanced degradation of tetherin through lysosomal and/or
proteasomal pathways have all been reported to play important
roles (Douglas et al., 2009; Dube et al., 2010; Goffinet et al.,
2009; Iwabu et al., 2009; Mangeat et al., 2009; Mitchell et al.,
2009; Van Damme et al., 2008).
Here we investigated the role of tetherin in primary human
macrophages using immunofluorescence and electron micro-
scopic methods, in order to define the role of tetherin in the
virus-containing compartment (VCC). Tetherin was markedly
upregulated followingmacrophage infection, and relief of restric-
tion of particle release by Vpu was incomplete. Remarkably,
VCCs in infected macrophages were highly enriched in tetherin,
and depletion of tetherin caused a dramatic reduction and
redistribution of the VCC. Along with this redistribution, we
observed enhanced transmission of virus from macrophages
to T cells upon tetherin depletion.sevier Inc.
Figure 1. Tetherin Is Highly Concentrated
in Virus-Containing Compartments within
HIV-1-Infected MDMs
(A) MDMs were infected with VSV-G-pseudotyped
HIV-1 R8-BaL. Eight days postinfection, cells were
fixed and immunolabeled for HIV-1 Gag (red, anti-
CA183) and tetherin (green, anti-tetherin). Bars
represent 15 mm.
(B) MDMs were infected with HIV-1 BaL biological
stock. Eight days postinfection, cells were fixed
and immunolabeled for HIV-1 Gag (red, anti-
CA183) and tetherin (green, anti-tetherin). Bars
represent 16 mm.
(C–E) MDMs were infected with VSV-G-pseudo-
typedHIV-1 R8-BaL for 8 days followed by fixation,
permeabilization, and immunostaining for Vpu (red,
anti-Vpu) and Gag (green, anti-CA183) in (C); for
TGN (red, anti-TGN) and Gag (green, anti-CA183)
in (D); and for Vpu (cyan, anti-Vpu), Gag (green,
anti-CA183), and tetherin (red, anti-tetherin) in (E).
Bars represent 11 mm. See also Figure S1.
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Tetherin Is Highly Concentrated in Virus-Containing
Compartments within HIV-1-Infected MDMs
We hypothesized that tetherin may play a role in the formation
of VCCs in HIV-infected macrophages. To test this hypothesis,
we first examined the subcellular localization of tetherin in
MDMs. In HeLa and other epithelial cell lines, tetherin is found
within the trans-Golgi network (TGN), within recycling endo-
somes, and at the plasma membrane, without significant
concentration in late endosomes (Dube et al., 2009; HabermannCell Host & Microbe 12, 360–372, Seet al., 2010; Le Tortorec and Neil, 2009). In
HIV-infected MDMs, we observed teth-
erin on the cell surface as well as in large
intracellular compartments (Figure 1). We
noted that tetherin was highly concen-
trated in intracellular compartments and
often appeared as more than a single
population in the cell (Figure 1A). Infected
MDMs double-labeled for tetherin and
Gag demonstrated a substantial level of
colocalization between the two proteins
(Figure 1A). The colocalization appeared
to occur within a subset of tetherin-rich
compartments and was consistently
observed in macrophages from multiple
donors. To confirm this result, we
repeated the experiment using a biolog-
ical stock of nonpseudotyped HIV-1 BaL
instead of VSV-G-pseudotyped virus
and obtained identical results (Figure 1B).
In parallel, we also performed the same
experiment but replaced the tetherin
primary antibody with prebleed serum
from the same animal or omitted the
primary antibody. In both of these
controls, we failed to observe staining of
this compartment (data not shown). Ithas been reported previously that HIV-1 Vpu colocalizes with
tetherin in the TGN of infected cells (Dube et al., 2009; Le Tor-
torec and Neil, 2009). In addition, HIV-1 Vpu may counteract
tetherin by sequestering tetherin in the TGN (Dube et al., 2009,
2010; Le Tortorec and Neil, 2009). To examine the possibility of
potential interactions between Gag, Vpu, and tetherin in infected
MDMs, we performed a series of immunostaining studies and
documented the cellular distribution of Gag, Vpu, and tetherin
in infected MDMs. We first double-labeled MDMs with anti-
bodies against Gag and Vpu or Gag and TGN. Gag and Vpu
were found within distinct compartments in infected MDMs,ptember 13, 2012 ª2012 Elsevier Inc. 361
Cell Host & Microbe
Tetherin in HIV-Infected Macrophageswith no detectable colocalization between the two (Figure 1C).
The VCC identified by Gag antibody staining was entirely distinct
from the TGN (Figure 1D). We then performed a triple staining
experiment in which tetherin, Gag, and Vpu were labeled. Teth-
erin was found in two compartments inside the cell, one that
colocalized with Gag (the VCC) and another that colocalized
with Vpu (the TGN) (Figure 1E). As an additional control, we
examined the distribution of tetherin and protein disulphide
isomerase (PDI), an ER marker. Tetherin did not colocalize with
PDI (see Figure S1 online).
Tetherin Colocalizes with Markers of Two Distinct
Intracellular Compartments in MDMs: The
Multivesicular Body and TGN
To further define the exact compartments in which tetherin and
HIV-1 Gag colocalize, we performed immunostaining for tetherin
and various cellular markers in both uninfected and HIV-infected
MDMs. Cellular markers that we tested included CD81, CD9,
CD63, and LAMP-1, as well as the TGN marker TGN46 and ER
marker PDI as described above.
In uninfected MDMs, we observed a significant level of coloc-
alization between tetherin and both of the MVB markers, CD81
andCD9 (Figure 2A andFigure S1,with quantitation in Figure 2C).
We noticed that although the vast majority of CD81 and CD9
colocalized with tetherin, only a subset of intracellular tetherin
colocalized with CD81 and CD9. At the same time, we again de-
tected a substantial but partial colocalization between tetherin
and the TGN marker, TGN46 (Figure 2A). These results indicate
that in uninfected macrophages, tetherin resides in two distinct
compartments in MDMs: the TGN and the CD81/CD9-positive
endosome. Interestingly, immunostaining performed for CD63
and LAMP-1 in uninfected MDMs failed to identify a significant
colocalization between tetherin and these late endosome/MVB
markers (Figure 2A, CD63 and LAMP-1 rows). LAMP-1 and
CD63 were located in close proximity but did not directly overlap
with tetherin in these uninfected cells.
Next, we examined HIV-infected MDMs for the same set of
markers. We observed a strong colocalization between a subset
of intracellular tetherin and the tetraspanins CD81 and CD9,
similar to what had been seen in uninfected macrophages (Fig-
ure 2B and Figure S1). In contrast to the uninfected cells,
however, immunostaining for CD63 and LAMP-1 in infected
MDMs revealed a significantly enhanced level of colocalization
between CD63, LAMP-1, and tetherin (Figure 2B, CD63 and
LAMP-1 rows). The pattern of colocalization between tetherin
and CD63 or LAMP-1 was similar to what we observed between
tetherin and CD81/CD9, such that a subpopulation of tetherin
colocalized almost completely with the intracellular CD63 or
LAMP-1. HIV infection therefore led to an enrichment of CD63
and LAMP1 in the tetherin/CD9/CD81-rich compartment, remi-
niscent of previously reported findings that HIV alters this
compartment (Deneka et al., 2007).
To quantify these observations, we measured the partial co-
localization coefficients (Mx and My) between tetherin and each
cellular marker using the colocalization function of Volocity
5.2.1 (Manders et al., 1993). Infected and uninfected macro-
phages demonstrated a high degree of colocalization for
CD81, CD9, and TGN with tetherin (Figure 2C), while ER colocal-
ization was minimal, consistent with the impression from362 Cell Host & Microbe 12, 360–372, September 13, 2012 ª2012 Elindividual images. HIV-1 infection increased the degree of coloc-
alization of CD63 and LAMP-1 with tetherin as indicated by
a significant increase (p < 0.0001) in colocalized pixels (Fig-
ure 2C). In infected MDMs, the My values for the degree colocal-
ization of CD63 and LAMP-1 with tetherin were increased by
3-fold in comparison with uninfected MDMs.
Triple staining for Gag, tetherin, and cellular compartment
markers confirmed that a substantial intracellular subset of
tetherin colocalized with HIV-1 Gag in CD81- and CD63-
enriched VCCs, and that a separate population of tetherin
was found in the TGN (Figure S2). In contrast with the strong
colocalization between Gag and tetherin (My = 0.75 ± 0.18),
the level of colocalization between Gag and ER was minimal
(My = 0.09 ± 0.04). The level of colocalization between Gag/ER
and Gag/tetherin was significantly different (p < 0.0001). Alto-
gether, these results indicate that in HIV-infectedMDMs, tetherin
resides in two distinct compartments: the TGN, where it colocal-
izes with Vpu; and the VCC, where it colocalizes with Gag and
markers of the MVB.
Tetherin Links Virions to the Limiting Membranes
of Virus-Containing Compartments in Human
Macrophages
We and others recently demonstrated that tetherin forms a link
between chains of extracellular virions and the plasma
membrane on the surface of the A3.01 T cell line (Hammonds
et al., 2010) or HeLa cells (Fitzpatrick et al., 2010). We next
sought to examine the location of tetherin at the ultrastructural
level in human macrophages using immuno-EM techniques. In-
fected macrophages were fixed, embedded in resin, and pre-
pared for thin sections, followed by postembedding immunogold
labeling using anti-tetherin antiserum or preimmune control sera
as the primary antibody. We found only rare gold particles in the
cytoplasm of cells outside of the VCCs, while the presence of
beads between numerous virion particles within the VCCs
was evident (Figures 3A–3C). As in our previous report
examining extracellular particle tethering, some extended
filamentous strings studded with tetherin were evident in the
VCC (Figures 3D and 3E). More frequently, tetherin was
identified at the interface between particles (Figures 3F, 3H,
3I). Tetherin was also prominently found connecting particles
to the periphery of the compartment, an apparent connection
with the limiting membrane (Figures 3E–3G). The specificity of
labeling of the VCC was confirmed by a low background rate
of nanogold particles within the compartments when preimmune
rabbit serum was employed (Figure 3J–3L). Purity of macro-
phages utilized in these and other experiments was greater
than 91% (Figure S3).
Tetherin Expression Is Upregulated Following Infection
of MDMs and Is Incompletely Downregulated by Vpu
Particle output from MDMs is enhanced following infection with
viruses bearing an intact vpu gene (Balliet et al., 1994; Schubert
et al., 1995), suggesting that Vpu’s antagonism of tetherin is
functional in this cell type. We similarly documented an increase
in p24 release over time from MDMs following infection with
NL4-3 versus NLUdel (Figure 4A). This difference was very repro-
ducible and was seen in MDMs from multiple different donors.
Remarkably, cellular tetherin levels increased following infectionsevier Inc.
Figure 2. Subcellular Distribution of Tetherin in Uninfected MDMs
(A) Uninfected MDMs were fixed and immunolabeled for cellular markers (red, anti-TGN46, anti-CD81, anti-CD63, and anti-LAMP-1) and tetherin (green,
anti-tetherin). Note lack of colocalization with CD63 and LAMP-1. Bars represent 16 mm. Images selected are representative of the major findings frommore than
100 cells examined in five independent experiments.
(B) MDMs were infected with VSV-G-pseudotyped HIV-1 NL4-3. Eight days postinfection, cells were fixed and immunolabeled for cellular markers (red, anti-
TGN46, anti-CD81, anti-CD63, and anti-LAMP-1) and tetherin (green, anti-tetherin). Bars represent 15 mm for LAMP-1 panel and 16 mm for the remaining panels.
(C) Quantitation of colocalization between cellular marker and tetherin in uninfected (filled bars) or infected (white bars) MDMs. The partial correlation coefficient
and standard deviation shown represent the degree of colocalization derived from images of at least ten representative cells. Results were shown as mean ± SD.
Statistical comparison between the groups were performed by unpaired t test using GraphPad Prism 5. See also Figure S2.
Cell Host & Microbe
Tetherin in HIV-Infected Macrophagesand remained elevated over baseline for more than 6 days in
macrophages following infection with either NL4-3 or NLUdel
(Figure 4B). The magnitude and timing of upregulation varied
slightly from donor to donor, but the upregulation was detectable
in every donor examined (n > 10). The use of VSV-G itself wasCell Host & Mnot the stimulus for tetherin upregulation, as supernatants from
VSV-G-transfected cells did not enhance tetherin expression
(Figure S4A). To further verify this, we infected MDMs from
multiple donors with PBMC-propagated HIV-1 BaL without
pseudotyping, and confirmed that the upregulation wasicrobe 12, 360–372, September 13, 2012 ª2012 Elsevier Inc. 363
Figure 3. Immunoelectron Microscopic
Localization of Tetherin within the Virus-
Containing Compartment in Macrophages
MDMs were infected with VSV-G-pseudotyped
HIV-1 NL4-3. Cells were harvested at day 8,
fixed, embedded, and sectioned. Sections
were etched with H2O2 and labeled with 6 nm
gold beads using anti-tetherin antisera using
methods previously established (Hammonds
et al., 2010).
(A) Multiple nanogold beads between particles at
low power within a VCC; bar, 200 nm. Arrows
were added to point out beads.
(B) Higher-magnification view of left half of (A);
bar, 100 nm.
(C) Higher-magnification view of upper right
portion of (A); bar, 100 nm.
(D) Extended tether and beads between particles;
bar, 100 nm.
(E) Tetherin at base of particles, between limiting
membrane and particles within intracellular com-
partment in macrophages. Bar, 100 nm.
(F) Tetherin immunolabeling at base of particle
and between particles within intracellular com-
partment in macrophages. Bar, 100 nm.
(G) Tetherin linking particle to the limiting mem-
brane of a VCC; bar, 100 nm.
(H and I) Additional views of tetherin labeling
within VCCs, on surface of virions and between
virions.
(J) VCC, control section employing preimmune
serum and immunogold labeling otherwise iden-
tical to that in (A)–(I). Bar, 500 nm.
(K) Detail of same VCC as in (J) with control (pre-
immune) labeling; bar, 100 nm.
(L) Gold particles found within VCCs of HIV-
infected macrophages, mean ± SD, using specific
anti-tetherin sera (black) or pre-immune sera
(gray). Twenty consecutive VCCs with virions were
assessed for each label, and normalized by total
number of visualized particles. See Figure S3
for assessment of macrophage purity by flow
cytometry.
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The increase in total cellular tetherin was diminished but not
prevented by Vpu, as tetherin levels at day 8 to day 12 postinfec-
tion were greater in cells infected with NLUdel than in those in-
fected with NL4-3. Quantitative analysis of western blots
confirmed a consistent upregulation of tetherin in HIV-1-infected
MDMs frommultiple donors (Figure S4B). In stark contrast to the
phenotype seen in HeLa cells, cell-surface levels of tetherin in
MDMs were not diminished following infection with NL4-3
but actually increased (Figure 4D). Vpu failed to prevent the
increase in cell surface tetherin levels as indicated in repeated
experiments by the increased mean fluorescence intensity of
surface-stained cells (Figure 4D, lower right). In individual exper-
iments, the increase in cell-surface tetherin was greater when
MDMs were infected with NLUdel, although taken together the
difference was not statistically significant (Figure 4D, lower right).
In parallel, we infected HeLa cells with the same viruses and
observed a significant decrease in cell-surface tetherin following364 Cell Host & Microbe 12, 360–372, September 13, 2012 ª2012 ElNL4-3 but not NLUdel infection (Figure 4D, HeLa). These results
indicate that although Vpu does enhance particle release from
MDMs, Vpu’s ability to downregulate tetherin in MDMs is incom-
plete as compared with model cell lines such as HeLa. Further-
more, Vpu is unable to prevent the upregulation of cellular
tetherin expression that occurs following infection with HIV. We
also measured total tetherin levels by flow cytometry, and this
approach confirmed that total tetherin is upregulated in MDMs
in a similar manner to the surface upregulation (Figures S4C–
S4E, right panels), while NL4-3-infected HeLa cells demon-
strated a decrease in both surface and total tetherin levels
(Figures S4C–S4E, left panels).
Tetherin Knockdown Promotes Particle Release from
HIV-Infected MDMs Even in the Presence of Vpu
The colocalization and immuno-EM data described above
demonstrated that tetherin is enriched within the VCC in macro-
phages and appears to tether virions in this compartment. Tosevier Inc.
Figure 4. Vpu and Tetherin in Infected
MDMs
(A) Particle release fromMDMswas assessed over
time using a p24 antigen ELISA. The efficiency of
release was plotted as percentage of extracellular
p24/total p24 from three experiments. The
majority of p24 was retained in macrophages in-
fected with either NL4-3 or NLUdel, and total
amounts of p24 (cell + sup) were similar. Right-
sided graph represents one of the experiments,
presented as released p24 antigen. Error bars
represent SD.
(B) Western blot of tetherin and actin over time
following infection of MDMs.
(C) Western blot of tetherin and actin over time
from MDMs infected with HIV-1 BaL. MDMs were
infected with HIV-1 BaL, and cell lysates were
harvested at the indicated time points. Western
blots were performed as mentioned above.
Results from two donors were shown as repre-
sentatives of five independent experiments.
(D) Cell-surface levels of tetherin following infec-
tion with NL4-3 (dashed line) or NLUdel (solid line).
Cells were stained with anti-p24 antibody to allow
gating on the infected population. Results of indi-
vidual experiments in HeLa (left) and MDMs (right)
are shown. Below are %MFI with error bars rep-
resenting SD at 48 hr postinfection (HeLa) or
4 days postinfection (MDMs), with results from
three independent experiments plotted. Statistical
comparison between the groups was performed
by unpaired t test using GraphPad Prism 5. See
also Figure S4.
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tetherin in MDMs using siRNA and measured the effects on
particle output and on the volume of the VCC. Figure 5A is
a representative example of the tetherin knockdown achieved,
in which the MDMs were first treated with tetherin or control
siRNA three times to achieve a potent depletion of endogenousCell Host & Microbe 12, 360–372, Setetherin, followed by NL4-3 infection.
The tetherin level in MDMs was signifi-
cantly reduced (70%–80%) and per-
sisted for the time span of the experiment
(Figure 5A). As demonstrated in the
control knockdown cells, control siRNA
and the siRNA transfection reagent
did not affect tetherin expression in
MDMs, which increased after infection
(Figure 5A).
We then analyzed the efficiency of
particle release in siRNA-treated, HIV-
infected MDMs. NLUdel was very poorly
released from MDMs transfected with
control siRNA (Figure 5B, open dia-
monds). In contrast, following tetherin
depletion, particle release of NLUdel
was significantly increased (Figure 5B,
closed diamonds). Interestingly, the level
of NLUdel release in tetherin knockdown
MDMs was comparable to the level ofNL4-3 release in control knockdownMDMs (Figure 5B, compare
closed diamonds and open squares). Although NL4-3 release
from MDMs was greater than that of NLUdel, tetherin depletion
had a clear added effect on particle release (Figure 5B, closed
squares). The additive effect of tetherin knockdown and Vpu in
particle release from infected MDMs for NL4-3 confirmed ourptember 13, 2012 ª2012 Elsevier Inc. 365
Figure 5. Effects of Tetherin Knockdown on
Particle Release and Cell-Cell Transmission
from MDMs
(A) MDMs were transfected with tetherin siRNA or
control siRNA three times followed by NL4-3
infection. Infected cells were harvested at indi-
cated time points postinfection, lysed, and
analyzed by western blotting using rabbit anti-
tetherin or mouse anti-actin antiserum.
(B) Particle release from tetherin siRNA or control
siRNA treated and infected MDMs was assessed
over time using a p24 antigen ELISA. The effi-
ciency of release is plotted as percentage of
extracellular p24/total p24 from three experi-
ments, with standard deviations indicated.
(C) Western blot of tetherin and actin from MDMs
in cell-cell transmission assays. MDMs were
treated with control or tetherin siRNA followed by
NL4-3 infection.
(D) H9 cells in contact with infected MDMs were
harvested and fixed at the indicated time points,
followed by labeling for CD3 and HIV-1 Gag. Flow
cytometry was performed to analyze the per-
centage of infected H9 cells by gating on Gag- and
CD3-positive cells. Error bars represent SD.
(E) Western blot of tetherin and actin of MDMs in
cell-cell transmission assays using the Transwell
system.
(F) H9 cells were harvested from the insert cham-
bers and the bottom chambers separately and
labeled for CD3 and HIV-1 Gag. Flow cytometry
was performed to analyze the percentage of H9
cells that were CD3 and Gag positive. Cell-cell
transmission events were derived by subtracting
the cell-free transmission events from the total
transmission events. Error bars represent SD.
Statistical comparison between the groups was
performed by unpaired t test using GraphPad
Prism 5.
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effect of tetherin in infected MDMs, and that residual restriction
of release by tetherin remained.
Currently the role of tetherin in cell-cell transmission remains
incompletely defined. To elucidate the role of tetherin in cell-
cell transmission from infected MDMs, we first performed366 Cell Host & Microbe 12, 360–372, September 13, 2012 ª2012 Elsevier Inc.a transmission assay to evaluate cell-
cell transmission by gently centrifuging
H9 T cells onto an adherent monolayer
of infected MDMs and quantifying in-
fected H9 cells by flow cytometry. Teth-
erin siRNA treatment successfully
inhibited tetherin expression in the donor
MDMs (Figure 5C). H9 cells that were
cocultured in contact with tetherin
siRNA-treated MDMs were infected at a
higher efficiency compared with H9 cells
cocultured with control siRNA-treated
MDMs (Figure 5D). At 72 hr after the
coculture, 4.8% ± 1.04% of H9 cells
cocultured with tetherin siRNA-treated
MDMs were infected, compared with2.6% ± 0.05% of H9 cells cocultured with control siRNA-treated
MDMs (Figure 5D). This experiment suggested to us that tetherin
knockdown promoted cell-cell transmission from infected
MDMs to H9 cells, although some cell-free transmission was
also possible by this method. Next, we employed a Transwell
cell-culture system and refined our cell-cell transmission study.
Figure 6. Effect of Tetherin Knockdown on
the Virus-Containing Compartments in
MDMs
(A–C) MDMs were transfected with control siRNA
three times followed by infection with VSV-G-
pseudotyped NL4-3. At day 4 postinfection, cells
were fixed and immunolabeled for CD9 (red, anti-
CD9) and HIV-1 Gag (green, anti-CA183). Bars,
16 mm.
(D–I) MDMs were transfected with tetherin siRNA
three times followed by infection with VSV-G-
pseudotyped NL4-3. At day 4 postinfection, cells
were fixed and immunolabeled for CD9 (red, anti-
CD9) and HIV-1 Gag (green, anti-CA183). Bars,
16 mm.
(J) Quantitation of the volume of the VCCs in in-
fected MDMs with tetherin knockdown or control
knockdown. The volume of the VCCs within each
cell for 30 cells was calculated using the Volocity
5.5.1 measurements module.
(K) Quantitation of the volume of individual VCCs
within infected MDMs with tetherin knockdown or
control knockdown. Colocalized pixels between
CD9 and Gag were determined as above and
volumes calculated for individual VCCs, counting
150 VCCs for each arm of the experiment. Error
bars in (J) and (K) represent SD.
(L) Particle release from MDMs from the same
donor in the experiment presented here was as-
sessed over time using a p24 antigen ELISA.
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MDMs in Transwell plates were first infected with HIV, followed
by addition of H9 cells to the top chamber (no MDMs) or the
bottom chamber (in contact with MDMs) on day 2 postinfection.
Infected H9 cells detected from the top chamber represented
cell-free transmission events, and infected H9 cells detected
from the bottom chamber represented total transmission events
(cell-cell + cell free). Cell-cell transmission events were derived
by subtracting the cell-free transmission events from the total
transmission events. Western blots from harvested MDM cell
lysates again showed that tetherin siRNA treatment successfully
inhibited tetherin expression in MDMs in the Transwell plates
(Figure 5E). siRNA silencing of tetherin in MDMs promoted cell-
cell transmission from infected MDMs to H9 cells, with 4.5% ±
0.5% of H9 cells cocultured with tetherin siRNA-treated MDMs
infected versus 2.8% ± 0.4% of H9 cells cocultured with control
siRNA-treated MDMs (Figure 5F). These two methods yielded
similar results, indicating that tetherin restricts cell-cell transmis-
sion from infected MDMs to T cells.Cell Host & Microbe 12, 360–372, SeTetherin Knockdown Inhibits the
Formation of the Virus-Containing
Compartments in Infected MDMs
In order to investigate the effect of teth-
erin knockdown on the VCCs in infected
MDMs, we applied quantitative confocal
microscopy on the siRNA-treated, HIV-
infected MDMs. MDMs were treated
with tetherin siRNA or control siRNA fol-
lowed by NL4-3 infection, and harvested
at day 4 postinfection. HIV Gag colocali-
zation with CD9 was used as a measureof the VCC, and the volume of the VCC was measured using
3D image reconstructions of the Gag and CD9 colocalized
pixels. Control siRNA-treated MDMs visually resembled un-
treated MDMs, with large collections of Gag colocalizing with
CD9 in the VCC (Figures 6A–6C). Remarkably, the location and
size of the VCCwere altered in tetherin-depletedMDMs. In these
cells, the VCC size was diminished, and when present was found
as smaller (Figures 6D–6F) and often more peripheral puncta
(Figures 6G–6I). The average volume of the VCCs measured
from 30 control siRNA-treated MDMs on day 4 following
infection was 10.9 mm3, while the average volume of the VCCs
in tetherin-depleted MDMs was dramatically reduced to
3.2 mm3 (Figure 6J). This measurement was performed using
total (per cell) VCC volume. We also examined the average
volume of the individual VCCs, and these results confirmed the
marked reduction in size of the individual VCCs upon tetherin
depletion (Figure 6K). These results indicate that depletion of
tetherin markedly reduces the size and alters the distribution of
the VCCs in MDMs. Tetherin knockdown in these experimentsptember 13, 2012 ª2012 Elsevier Inc. 367
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experiments (Figure 6L).
Tetherin Upregulation in Infected MDMs Is
Nef Dependent and Is Not a Direct Consequence
of Type I Interferon Induction
Previous studies have reported that tetherin expression is highly
interferon inducible in a large number of cell types (Neil et al.,
2008). To understand the mechanism of tetherin upregulation
in infected MDMs, we examined the relationship between
type-I interferon production and tetherin expression in HIV-
infected MDMs. We were able to detect IFN-a induction in
supernatants from three out of six donors evaluated. The peak
of IFN-a was detected later than the upregulation of tetherin,
however, at day 8 postinfection (Figure 7A). Among the samples
in which IFN-a was detected, the average peak concentration
for NL4-3 and NLUdel-infected MDMs was 28.9 pg/ml and
16.5 pg/ml, respectively (Figure 7A), which would translate to
11.6 U/ml and 6.6 U/ml, according to themanufacturer’s calibra-
tion. IFN-awas not detected in supernatants fromMDMswith no
infection (Figure 7A). We detected a much higher level of
released IFN-a in the supernatant of poly(I:C)-treated MDMs
(Figure 7A), and this correlated with an upregulation of tetherin
on day 2 of poly(I:C) treated MDMs by western blotting (Fig-
ure 7B). In addition to IFN-a, we also tested the supernatants
for IFN-b with an IFN-b ELISA. However, in all six donors that
we tested for IFN-b, the level of IFN-b was below the detection
limit of the assay (data not shown). The level and timing of
IFN-a expression detected in our infected MDM cultures are
consistent with a previous report (Szebeni et al., 1991). Because
we did not detect production of IFN-a at early time points when
tetherin was highly upregulated, IFN-a did not appear to be the
cause for tetherin upregulation in infected MDMs. To further
assess this, we supplied uninfected MDMs with exogenous
human recombinant IFN-a in excess, and measured tetherin
expression from the treated cells at various time points. Tetherin
was not upregulated when the MDM culture was stimulated with
20 U/ml IFN-a, a level slightly higher than the highest we had
measured in MDM culture supernatants (Figure 7C). We next
treated MDMs with increasing amounts of IFN-a and found
that the minimum amount required for tetherin upregulation
was 50 U/ml (Figure 7D, Donor 2, lane 4) or 100 U/ml (Figure 7D,
Donor 1, lane 5). Because we had demonstrated together with
the Wu laboratory that HIV-1 Nef is involved in tetherin upregula-
tion in dendritic cells (Coleman et al., 2011), we then infected
MDMs with wild-type virus or virus lacking Nef expression
(NLdeltaNef), and measured tetherin expression at various time
points postinfection. Our result showed that in delta Nef-infected
MDMs, tetherin upregulation was largely absent (Figure 7E),
suggesting that HIV-1 Nef plays a role in tetherin upregulation
in infected MDMs as it does in dendritic cells.
DISCUSSION
Membranous compartments harboring large collections of
virus particles are frequently observed in HIV-1-infected
macrophages. These compartments are variably referred to as
virus-containing compartments (VCCs) or virus assembly
compartments, because in addition to mature virions, immature368 Cell Host & Microbe 12, 360–372, September 13, 2012 ª2012 Elvirus particles as well as active budding viral structures are
sometimes observed (Bennett et al., 2009; Orenstein et al.,
1988). In this study, we have identified tetherin as a component
of the VCC and provide evidence that tetherin plays a functional
role in this compartment.
The subcellular distribution of tetherin in macrophages is quite
distinct from that observed in other cell types. In epithelial cells
such as HeLa, tetherin localizes to the plasma membrane, the
TGN, and some early endosomal compartments, such as the
recycling endosome compartment. In macrophages, we now
demonstrate that tetherin is found largely on the plasma
membrane and in two intracellular sites: the TGN and the
CD81, CD9-enriched compartments where HIV virions accumu-
late (the VCC). HIV infection is not required to bring tetherin into
this tetraspanin-enriched intracellular compartment, as indi-
cated by the strong presence of tetherin colocalizing with
CD81 and CD9 in uninfected MDMs. Instead, following HIV-1
infection, HIV particles accumulate in this tetherin/CD81/CD9-
rich compartment, and CD63 and LAMP-1 are simultaneously
enriched in the VCC. The enrichment of CD63 in the VCC is
consistent with the previous observation that HIV alters the
CD81+/CD9+ compartment and results in relocalization of
CD63 into this compartment (Deneka et al., 2007). It was recently
shown that tetherin functions by physically attaching to virus
particles (Fitzpatrick et al., 2010; Hammonds et al., 2010;
Perez-Caballero et al., 2009). Our data now indicate that physical
tethering of particles occurs within the VCC as well. We found
tetherin linking particles to the limiting membrane and linking
particles to each other within the VCC.
Depletion of tetherin in macrophages created a markedly
diminished VCC in macrophages, and a redistribution of the
remaining intracellular viral particles into smaller, more periph-
eral compartments. This is consistent with a model in which
tetherin is required for the formation of the VCC, or at least in
trapping and retaining particles in this pre-existing compart-
ment. Tetherin may trap particles peripherally, followed by endo-
cytosis into the VCC, or tether and retain particles within the VCC
as budding occurs within this compartment. We suggest from
depletion studies that tetherin plays an integral role in the VCC,
and that the upregulation of tetherin that follows HIV infection
of MDMs is also an important factor in the formation of the
VCC. The population of tetherin in the VCC appears to be
completely distinct from the population in the TGN, and fails to
colocalize with Vpu. This population may be more stable and
resistant to degradation by Vpu than is the TGN-associated or
actively recycling tetherin population.
Vpu was unable to completely counteract the upregulation of
tetherin in macrophages, although it was able to limit the magni-
tude of tetherin upregulation, resulting in enhanced particle
release compared with that seen with Vpu-deficient virus infec-
tion. Thus, the upregulation of tetherin in infected macrophages
may result in enhanced sequestration of viruses in intracellular
compartments, even when Vpu is expressed. The inability of
Vpu to efficiently counteract tetherin in macrophages was
especially evident when we observed an enhancement of
particle release upon tetherin depletion, even in the case of
Vpu-expressing viruses.
Miyagi and coworkers previously demonstrated that Vpu
downregulates cell surface tetherin in macrophages (Miyagisevier Inc.
Figure 7. Mechanism of Tetherin Upregulation in Infected MDMs
(A) MDMs were infected with VSV-G-pseudotyped NL4-3 or VSV-G-pseudotyped NLUdel. MDMs from the same donors were stimulated with poly(I:C) by adding
25 ug/ml poly(I:C) in the cell cultures or were left untreated. IFN-a levels from the supernatants were measured by IFN-a ELISA. Error bars represent SD.
(B) Western blot of MDMs treated with 25 mg/ml high-molecular-weight poly(I:C). MDMs were harvested at indicated time points post-poly(I:C) treatment, lysed,
and analyzed by western blotting using rabbit anti-tetherin or mouse anti-actin antiserum.
(C) Western blot of MDMs treated with 20 U/ml human recombinant IFN-a.
(D) MDMswere treated with 0, 10, 25, 50, 100, 500, or 1,000 U/ml human recombinant IFN-a. Twenty-four hours after the IFN-a treatment, MDMswere harvested
and analyzed by western blotting.
(E) MDMs were infected with VSV-G-pseudotyped NL4-3 or VSV-G-pseudotyped NL4-3 delNef. Cell lysates were harvested at the indicated time points (days)
and analyzed by western blot for tetherin and actin expression.
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upregulated following infection. The difference in these findings
is likely attributable to the timing of the cell harvest for analysis
following infection. We documented an increase in total tetherin
levels for more than 6 days postinfection, after which tetherin
levels return to baseline. Miyagi and coworkers harvested
MDMs at 24 days postinfection, and did not report on earlier
times postinfection (Miyagi et al., 2009).
Upregulation of tetherin in MDMs occurred at days 2–4
following HIV infection and did not correlate with release of
a- or b-interferon. It is likely that intracellular pathogen recogni-
tion is occurring to stimulate this upregulation. Bego and
colleagues have recently shown that stimulation of interferon
regulatory factor 7 can upregulate tetherin expression in the
absence of interferon signaling (Bego et al., 2012). It is intriguing
to note that TRIM5a itself serves as a pathogen recognition
receptor (Pertel et al., 2011), raising the possibility that tetherin
could act in a similar manner. In our study, HIV Nef was required
to elicit tetherin upregulation, as has been shown previously for
both dendritic cells and macrophages (Schindler et al., 2010;
Wu et al., 2004). Our results suggest that the high levels of
induced tetherin in HIV-infected MDMs can explain the finding
that even wild-type, Vpu-expressing virus in MDMs accumulates
in the intracellular VCC. Vpu is unable to counteract tetherin
efficiently in MDMs, leading to tetherin-mediated trapping of
virus within the VCC.
VCCs in macrophages and in dendritic cells have been sug-
gested to be sources of virus that are available to mediate
cell-cell spread upon contact with the appropriate target cells
(Gousset et al., 2008; Hubner et al., 2009; Lekkerkerker et al.,
2006; Marsh et al., 2009; Piguet and Steinman, 2007; Yu et al.,
2008). The presence of tetherin in VCCs in macrophages and
the physical tethering of particles within this compartment is
likely to have impact in how this compartment participates in
cell-cell transmission events. We now demonstrate that the
tethered virions within the VCC in macrophages are inhibited
in infecting T lymphocyte target cells. Depletion of tetherin in
HIV-infected MDMs led to significant increase in cell-cell trans-
mission in our study. These results are in agreement with the
findings of Casartelli and colleagues, who demonstrated that
tetherin inhibits transmission of Vpu-deficient virus from infected
cells and target T lymphocytes (Casartelli et al., 2010). Although
macrophages were not examined in their study, they showed
that transmission across the infectious synapse was inhibited,
while polarization of viral particles to the contact site was not in-
hibited. Jolly and colleagues, in contrast, found that tetherin did
not diminish cell-to-cell spread of virus (Jolly et al., 2010).
Surprisingly, depletion of tetherin in their hands diminished the
formation of the virologic synapse and decreased cell-cell
spread of virus. They concluded that tetherin might in some
circumstances actually enhance virus spread rather than inhibit
spread. These authors were not examining MDMs, which may
explain some of the contradictory conclusions of their study
versus our study and the Casartelli study. It remains to be
determined whether the large collections of tetherin-associated
virions in human macrophages can be transmitted to target
cells such as T lymphocytes, or whether the enhanced cell-
cell transmission events seen upon tetherin knockdown are
occurring from viruses assembling on the plasma membrane370 Cell Host & Microbe 12, 360–372, September 13, 2012 ª2012 Elthat escape tethering and subsequent delivery into intracellular
compartments.
In summary, we demonstrate that tetherin is highly enriched at
the site of HIV particle accumulation or assembly in infected
macrophages, and that tetherin is a physical tether in this
compartment as it is on the plasma membrane of T cells. Deple-
tion of tetherin markedly diminished the size and altered the
distribution of the VCC, suggesting that tetherin is required for
its formation. Tetherin depletion in HIV-infected MDMs en-
hanced cell-cell transmission of HIV. Understanding further
mechanistic details of the role of tetherin in HIV retention or
release in macrophages, and of the reduced ability of Vpu to
counteract tetherin in this cell type, will be important in efforts
to eradicate potential reservoirs of HIV in infected individuals
and in understanding cell-to-cell transmission events in vivo.
EXPERIMENTAL PROCEDURES
Preparation of Monocyte-Derived Macrophages
Peripheral blood was obtained from healthy volunteer donors according to
a protocol approved by the Emory University Institutional Review Board
(IRB). Peripheral blood mononuclear cells (PBMCs) were obtained from the
buffy coat after Ficoll centrifugation and were allowed to adhere to plastic
surface coated with poly-D-lysine (Sigma Aldrich, Saint Louis, MO, USA). Non-
adherent PBMCs were washed away after 1 hr. Adherent monocytes were
maintained in RPMI-1640 supplemented with 10% FBS, 100 ug/ml strepto-
mycin, 100 U/ml penicillin, 2 mM glutamine, 1% sodium pyruvate, 1% nones-
sential amino acids, and 1U/ml GM-CSF (Cell Sciences, Canton, MA, USA).
Monocytes were maintained in the supplemented media for 8 days for differ-
entiation into macrophages, during which the media was replaced every
2 days. The purity of the macrophage population was assessed at day 10 by
CD14 and CD68 staining and was on average greater than 93% (Figure S3).
Virus Stocks and Infections
Vesicular stomatitis virus G glycoprotein (VSV-G)-pseudotyped or wild-type
HIV-NL4-3, HIV-NLUdel, and HIV-NL4-3-delNef virus stocks were generated
by transfection of 293T cells. Some infections where noted were performed
with BaL biological stocks using one tissue culture infectious dose (TCID50)
per cell.
siRNAs and Tetherin Knockdown
Tetherin siGENOME SMARTpool siRNA and control siGENOME nontargeting
siRNA were purchased from Thermo Fisher Scientific (Dharmacon, Lafayette,
CO, USA). Transfection of siRNAs into monocyte-derived macrophages
(MDMs) was performed with the N-TER Nanoparticle siRNA Transfection
System (Sigma Aldrich, Saint Louis, MO, USA). For tetherin knockdown exper-
iments, freshly differentiated MDMs were treated with 100 nM tetherin siRNA
or control siRNA three times at 72 hr, 48 hr, and 24 hr prior to virus infection.
Supernatant and cell lysate from infected cells were harvested at days 0, 2,
4, 6, 8, 10, and 12 postinfection and stored at 80C until analysis.
Image Acquisition and Analysis
Two imaging stations equipped for live-cell imaging were employed in this
study. The first imaging station was a Nikon TE2000-U spinning-disc confocal
fluorescence microscope with automated stage and Hamamatsu EM-CCD
camera developed by Improvision under the control of the Volocity software.
The second imaging station was a Deltavision imaging system developed
by Applied Precision. The system was equipped with an Olympus IX70
microscope and a CoolSnap HQ2 digital camera under the control of the soft-
WoRx software. Imaging processing and deconvolution were performed using
softWoRx 3.7.0. Colocalization and partial colocalization measurements were
quantified with the colocalization module of Volocity 5.2.1. For the tetherin
knockdown experiments, colocalized pixels between Gag and CD9 were
determined with the colocalization module of Volocity 5.5.1. The volume and
the intensity of Gag among the colocalized pixels were calculated using thesevier Inc.
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Photoshop CS4, and Adobe Illustrator CS4 were used to analyze and adjust
the images.
Immunofluorescence Microscopy
MDMs were washed with PBS and fixed in 4% paraformaldehyde for 12 min
at RT. After fixation, cells were extensively washed including an overnight
wash at 4C. Cells were then permeabilized for 10 min with 0.2% Triton
X-100 and blocked in Dako blocking buffer for 30 min. Primary and secondary
antibodies were diluted in Dako antibody diluent to appropriate concentra-
tions. In general, cells were stained in primary antibodies for 1.5 hr and in
secondary antibodies for 45min. DAPI was used to stain the nuclei of the cells.
The coverslips were mounted in Gelvatol overnight and examined directly the
next day.
Electron Microscopy
MDMs cultured on ACLAR embedding film (Ted Pella, Redding, CA, USA) were
harvested at day 8, fixed in 4% paraformaldehyde for 1 hr followed by 4%
paraformaldehyde + 0.1% glutaraldehyde, and embedded in Epon. Sections
were etched with 5% H2O2 for 10 min and washed with deionized purified
H2O. Immunolabeling of tetherin was then performed using 6 nm gold beads
with a protocol similar to that described previously (Hammonds et al., 2010).
Images were obtained under a Hitachi H-7500 transmission electron micro-
scope at 75KV.
Flow Cytometry
HeLa and MDM cultures were infected with VSV-G pseudotyped NL4-3 or
NLUdel. Surface tetherin staining was performed with rabbit anti-tetherin
antiserum as described (Hammonds et al., 2010), with additional staining as
described in the Supplemental Experimental Procedures. Analysis was per-
formed on a FACSCanto flow cytometer (BD Biosciences) and using FlowJo
software (Treestar, Inc).
Cell-Cell Transmission Studies
Transmission of virus from infected MDMs was performed by gently centri-
fuging H9 cells onto MDMs in 24-well plates (method one) or by using Trans-
well culture plates with H9 cells and MDMs in contact (bottom chamber)
or separated by a 0.4 mm filter (H9s in top chamber). For both methods,
quantitation of transmission following the designated period of incubation
was performed by counting CD3+, p24+ cells on a FACSCanto flow cytometer
(BD Biosciences).
IFN-a ELISA and IFN-a Titration
IFN-a levels from MDM supernatants were measured by an IFN-a ELISA
kit fromMabtech (Mariemont, OH, USA). IFN-b levels fromMDM supernatants
were detected by an IFN-b ELISA kit from PBL Interferon Source (Piscataway,
NJ, USA).
Statistical Analysis
Statistical comparison between the groups was performed by unpaired t test
using GraphPad Prism 5. Differences were considered statistically significant
when p% 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
at http://dx.doi.org/10.1016/j.chom.2012.07.011.
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